Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live)

This medicine is authorised for use in the European Union.


Ervebo is a vaccine to protect adults and children aged 1 year and older against Ebola virus disease caused by the Zaire Ebola virus.

Ervebo contains a virus known as vesicular stomatitis virus which has been weakened and modified to contain a protein from the Zaire Ebola virus. The vesicular stomatitis virus itself has little or no effect on humans. The vaccine only contains one protein from the Zaire Ebola virus and cannot cause Ebola virus disease.

This EPAR was last updated on 23/08/2023

Authorisation details

Product details
Agency product number
Active substance
recombinant vesicular stomatitis virus (strain indiana) with a deletion of the envelope glycoprotein, replaced with the zaire ebolavirus (strain kikwit 1995) surface glycoprotein
International non-proprietary name (INN) or common name
Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live)
Therapeutic area (MeSH)
Hemorrhagic Fever, Ebola
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V. 
Date of issue of marketing authorisation valid throughout the European Union
Contact address

Waarderweg 39
2031 BN Haarlem
The Netherlands

Product information

16/08/2023 Ervebo - EMEA/H/C/004554 - II/0025

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Ervebo is indicated for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus.

The use of Ervebo should be in accordance with official recommendations.

Assessment history

Related content

How useful was this page?

Add your rating
4 ratings
1 rating
1 rating
1 rating